Review Article: Special Edition

Antigen specificity of invariant natural killer T-cells

Alysia M. Birkholza,b, Mitchell Kronenberga,b,∗

a Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, USA
b Division of Biological Sciences, University of California, San Diego, La Jolla, USA

Article history:
Received 14 May 2014
Accepted 16 November 2015
Available online 10 March 2016

Keywords:
Glycolipid
Immune system
Natural killer T-cells

Abstract

Natural killer T-cells, with an invariant T-cell antigen receptor α-chain (iNKT cells), are unique and conserved subset of lymphocytes capable of altering the immune system through their rapid and potent cytokine responses. They are reactive to lipid antigens presented by the CD1d molecule, an antigen-presenting molecule that is not highly polymorphic. iNKT cell responses frequently involve mixtures of cytokines that work against each other, and therefore attempts are underway to develop synthetic antigens that elicit only strong interferon-gamma (IFNγ) or only strong interleukin-4 responses but not both. Strong IFNγ responses may correlate with tighter binding to CD1d and prolonged stimulation of iNKT cells, and this may be useful for vaccine adjuvants and for stimulating anti-tumor responses. iNKT cells are self-reactive although the structure of the endogenous antigen is controversial. By contrast, bacterial and fungal lipids that engage the T-cell receptor and activate IFNγ from iNKT cells have been identified from both pathogenic and commensal organisms and the responses are in some cases highly protective from pathogens in mice. It is possible that the expanding knowledge of iNKT cell antigens and iNKT cell activation will provide the basis for therapies for patients suffering from infectious and immune diseases and cancer.

Introduction

General background

Initially described in mice [1], natural killer T-cells (NKT cells) have characteristics of both innate and adaptive immune cells. In mice, they were originally identified as cells that express NK 1.1, a marker for NK cells, which are a type of innate lymphocyte, expressed together with a αβ T-cell receptor (TCR), characteristic of adaptive immune cells. It is now known that all NKT cells do not express NK 1.1, and a subset of these lymphocytes expresses an invariant TCR α-chain that imparts a particular glycolipid specificity that is described further below. Cells with this phenotype were later confirmed to be present also in humans [2]. In the mouse, the human
NKT cell population is marked by a NK cell receptor, in this case, CD161, and it also expresses the αβ TCR with an invariant α-chain that shares significant homology with its mouse counterpart [3]. Comprising approximately 1% of peripheral lymphocytes in mice, NKT cells numbers in the peripheral blood mononuclear cells of humans tend to be less frequent, with a wide variation ranging from under 0.01% to 1% in healthy donors [4]; however, using CD161 and TCR expression as a definition of NKT cells, the frequency is much higher.

Because they express the αβ TCR, it was originally assumed that NKT cells would recognize peptides, similar to conventional T-lymphocytes that recognize peptides presented by major histocompatibility complex (MHC)-encoded antigen presenting proteins. Although early data and some recent data [5,6] indicated that NKT cells may be able to recognize peptides, it has been widely confirmed that NKT cells recognize and respond to lipids, mostly glycolipids. These antigens are presented not by MHC-encoded molecules but by CD1d, a related protein encoded outside the MHC gene complex [7]. This review will provide a brief overview of NKT cells, some of their known antigens and properties of the CD1d molecule.

**Type I and Type II natural killer T-cells**

Although there are T-lymphocytes having different specificities that express NK receptors, NKT cells are now generally defined as T-cells that recognize CD1d. The most commonly studied NKT cells are invariant NKT cells (iNKT cells) or Type I NKT cells, which express a nearly fixed or invariant TCR α-chain encoded by a Vα24-Jα18 rearrangement. This α-chain is co-expressed most frequently with a Vβ8.2, Vβ7, or Vβ2 TCR β-chain in mice. In humans, the Type I NKT cell TCR is formed by a nearly fixed Vα24-Jα18 (TRAV1-2-TRAJ18) rearrangement paired with a Vβ11 β-chain. The mouse and human invariant α-chains are true homologs, as are human Vβ11 and mouse Vβ8.

As a consequence, the specificity of mouse and human iNKT cells is highly conserved. This Type I NKT cell TCR has a preserved parallel binding motif radically different than the binding orientation of the TCR of mainstream CD4 or CD8 T-cells [8]. Type II NKT cells recognize CD1d as well; however, the α-chain is not highly restricted in diversity. Therefore, they do not have a single specificity, and they have been much less studied [9]. Here, we will focus on Type I NKT cells or iNKT cells.

**Biological response of invariant natural killer T-cells**

iNKT cells are very rapid responders when stimulated through their TCR, providing a cytokine burst within 90 min of in vivo stimulation [10]. Though TCR recognition of a lipid antigen presented by CD1d [Fig. 1], iNKT cells can induce a wide range of cytokines including T-helper Type 1 (Th1), T-helper Type 2 (Th2), and other responses. Activated iNKT cells not only secrete these cytokines but also induce other cells to secrete cytokines. The results from a number of studies demonstrate that the totality of the iNKT cell-induced immune response is dependent on the structure of the lipid antigen that is presented and recognized. Certain lipid antigens cause the production of predominately Th1 cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor, and other lipids lead to a more Th2 skewed pattern of cytokinetics that includes interleukin (IL-4), IL-5, and IL-13 [11].

**α-Galactosylceramide**

The most studied glycolipid that activates iNKT cells, also the first discovered, is α-galactosylceramide (αGalCer) [Figs. 1 and 2]. This is sometimes considered Th0 skewing lipid as iNKT cells that respond to this lipid robustly produce both IFN-γ and IL-4. αGalCer was originally identified by the Kirin Pharmaceutical Company in a screen of natural extracts for substances that prevent metastases of the mouse B16 melanoma, and it was shown to reduce liver metastases [12]. The structure was then synthesized and optimized by medicinal chemistry using the tumor metastases assay [13,14]. αGalCer has α-linked galactose, a phytosphingoid base chain with 18 carbons, and an acyl chain containing 26 carbons. αGalCer has not yet proven highly successful in human cancer studies, which may be due to the fact that it leads to both Th1 and Th2 cytokine responses [15,16]. These opposing responses may not promote an optimal anti-tumor response, which is more Th1-dependent. There are other explanations for reduced efficacy including the lower affinity of αGalCer/CD1d complexes for the human TCR compared to the mouse TCR [17]. For these reasons, there have been extensive efforts to develop other iNKT cell-activating lipids that can skew the cytokine response, especially in a Th1 direction. In addition, the type of antigen-presenting cell (APC) targeted may be critical, and in clinical trials, transfer of dendritic cells (DC) incubated with αGalCer generated a more robust iNKT cell response than αGalCer alone [16,18,19]. Continuing efforts to develop more effective glycolipids, delivery systems, and cell-based therapies using αGalCer remain underway.

**CD1d**

CD1d antigen-presenting molecule is a member of the family of CD1 proteins. This family is divided into two groups: Group 1 CD1 proteins (CD1a, CD1b, and CD1c) and Group 2 CD1 (CD1d) [20]. There is also a third, intermediate group member (CD1e). Whereas CD1a, CD1b, CD1c, and CD1d are found on the cell surface; CD1e is an intracellular protein that facilitates
glycolipid processing and presentation [21]. These proteins are found in humans and most other mammals; however, the mouse genome contains only two copies of the CD1d gene and no Group 1 CD1 proteins.

CD1d has a heterodimeric structure similar to MHC Class I antigen presenting molecules, with a heavy chain having three extracellular domains and a conserved β2-microglobulin subunit [22]. However, whereas MHC Class I molecules have shallow binding grooves capable of binding peptides that are typically nine amino acids in length; CD1d has a much deeper, narrower, and more hydrophobic groove containing two pockets, delineated as A' and F [Fig. 1]. This groove is perfectly suited to bind glycosphingolipids (GSLs) that have two hydrophobic chains that can anchor deeply within it. The phytosphingoid base chain of GSLs is localized to the smaller F' pocket, whereas the amide-linked fatty acid chain binds in the A' pocket. Within the A' pocket, the lipid chain must curl around a central point created by Cys12 and Phe70 [21]. The binding of the lipid chains within CD1d exposes the saccharyl head group that is recognized and forced into a fixed orientation by the iNKT cell TCR [23].

CD1d is synthesized in the endoplasmic reticulum (ER) and binds to self-phospholipids that allow it to traffic to endosomal compartments and the cell surface [21]. It has a tyrosine-containing cytoplasmic tail motif that mediates internalization to endosomes and eventually to lysosomes before recycling back to the cell surface. Exchange of self-antigens obtained in the ER with exogenous glycolipids and with self-lipids involved in the positive selection of iNKT cells in the thymus occurs within endosomal compartments [24,25], and for some exogenous antigens, also on the cell surface [26]. CD1d is expressed on a wide variety of hematopoietic series cells including B-cells, DC, macrophages, Langhans cells, monocytes, T-cells, and iNKT cells [27]. Some nonhematopoietic cells including hepatocytes and intestinal epithelial cells also express it [28,29]. Data indicate that DCs are the key activators of iNKT cells for exogenous glycolipids, except that various types of macrophages are important for presenting glycolipids in particular form such as on beads or in liposomes [30]. Recently, the CD8α+ DEC-205+ DC subset was identified as the APC type responsible for inducing both Th1 and Th2 responses [31]. According to these findings, increased expression of cell surface markers Rae-1 and CD86 by APCs leads to a Th1 cytokine profile while increased APC expression of PD-L2 serves to promote a Th2 cytokine profile [31].

Synthetic antigens

Head group modifications

The hydrophobic chains of iNKT cell lipid antigens are usually bound deep in the pockets of CD1d, and a polar head group is exposed for recognition by the iNKT cell TCR. The CD1d molecule stabilizes this head group through interactions with α1 and α2 helices [22]. In humans, position 153 of the α2 helix is a tryptophan amino acid, instead of a glycine in the homologous position (155) of mouse CD1d. Tryptophan, being a much bulkier amino acid, shifts the sugar head group into a slightly different position [23,32]. This is the main distinction between the structures of the GSL-CD1d complexes expressed by mice and humans.

Contacts between Asp153 and Thr156 of mouse CD1d and the 2' and 3'-hydroxyls of the αGalCer saccharide head group as well as the αGalCer O-glycosidic oxygen are important for ordering the sugar head group [33,34]. Because iNKT cell TCR recognizes the galactose head groups of GSLs, it is not surprising that altering this head group had deleterious effects on TCR binding. Modifications of the 2', 3', or 4' positions, particularly 2' diminished iNKT cell responses and TCR binding [35,36]. For example, while αGalCer and α-glucosyl ceramide (αGlucer) could both activate iNKT cells, which indicated that the axial versus equatorial orientation of the 4'-hydroxyl group is not critical; αGalCer was the most potent antigen. In contrast, α-mannosyl ceramide (αManCer) did not activate iNKT cells, indicating that the equatorial 2'-hydroxyl is critical [37]. Additional studies demonstrated the importance of the 2'-hydroxyl group in TCR recognition, as synthetic analogs of αGalCer with modifications of this position lacked antigenic activity [38]. The 3' position is more permissive as modifications at this position decreased but did not completely diminish activity [38–40]. Modifications of the 6' position are the most tolerated. This makes sense as crystal structures of the CD1d-lipid-TCR complex show that the 6' position does not make contacts with the TCR [17,41–43]. Tolerance for modifications at the 6' position were revealed in a study that compared responses to Gal (α1-2) GalCer with Gal (α1-6) GalCer, which are both GSLs with a disaccharide as opposed to monosaccharide head groups. While Gal (α1-2) GalCer required carbohydrate processing to remove the terminal galactose in order for antigenic activity, Gal (α1-6) GalCer did not [44]. Indeed, modification of the 6'-hydroxyl proved to be beneficial when PBS57, a 6'-deoxy-6'-acetamide αGalCer analog, was synthesized [45]. PBS57 was not only more easily solubilized than αGalCer, and it also induced a more potent in vivo cytokine response [46]. The 6' position is permissive for the addition of other bulky chemical groups as exemplified by the naphthylurea αGalCer molecule (NU-αGC) [Figs. 2 and 3] [47]. NU-αGC causes a robust Th1 cytokine response and reduces tumor metastases in mice even more effectively than αGalCer. It is very likely that NU-αGC binds in a more stable fashion to CD1d than αGalCer as the NU group serves as a “third anchor” of the lipid for binding to the CD1d molecule. It binds on top instead of deep in the CD1d groove, but without impeding the TCR [48]. Other 6' modifications such as NC-αGalCer, 4CPhC-αGalCer, and PyrC-αGalCer are also antigens that induce strong Th1 cytokine responses, correlated with a marked reduction of B16 melanoma metas-tasis to the liver [49]. PyrC-αGalCer, the most potent of these lipids, also shows novel and increased contacts with the both CD1d and the iNKT cell TCR. The 6' modifications have also served as tools for labeling GSLs with biotin or fluorophore, which has permitted analyses of their progress through endosomal compartments in cells [50].

Other synthetic alterations have been used to create α-carba-GalCer analogs [51]. In 2009, carbasugar and cyclitol analogs of αGalCer were generated, and another three analogs, RCAI-56 (a carba-α-galactose analog), RCAI-59 (a 1-deoxy-neo-inositol analog), and RCAI-92 (a 1-O-methylated analog), also were found to be Th1 skewing lipids [52]. The α-
carba-GalCer analog (RCAI-56), with the oxygen atom of galactose replaced with a methyl group, was shown to be an effective Th1 skewing molecule [53]. The authors proposed two mechanisms for this response. First, the methylene group replacing the oxygen atom interaction of the sugar head group makes the lipid less susceptible to degradation by hydroxylation, therefore allowing it to be presented for longer. Second, the oxygen of αGalCer may lead to a repulsive interaction with Pro28 of the TCR α-chain whereas the carbon of α-carba-GalCer would lead to an enhanced hydrophobic interaction [53]. This lipid also was tested in collagen-induced arthritis, an autoimmune model of rheumatoid arthritis in mice, and it was shown to provide protection against Th17-mediated autoimmune arthritis through the induction of Th1 cytokines [54].

HS44 is another GSL with head group modifications of αGalCer that induces a strong Th1 cytokine response. HS44 is an aminocyclitol molecule in which the sugar head group is a carba cyclitol ring that mimics glucose instead of galactose, and which has the O-glycosidic linkage replaced with an amide group [55]. Structural analysis and binding assays by surface plasmon resonance showed that when bound to CD1d this compound had a 14-fold weaker interaction with the iNKT cell TCR compared to αGalCer. Despite this, it caused a strong Th1 cytokine response and was effective at preventing tumor metastases [56].
Linkage modifications
As previously mentioned [55], the O-glycosidic linkage of αGalCer can be altered, and in doing so, can lead to some unique properties. In 2003, the oxygen bond was altered to a CH₂, theorizing that this GSL would be more resistant to α-galactosidase-mediated catabolism [57,58]. This compound, referred as C-glycoside [Fig. 2], was the first glycolipid shown to induce a strong Th1 cytokine response in mice [59], but it did not stimulate human iNKT cells very strongly. The ternary structure of C-glycoside/CD1d complexes bound to the iNKT cell TCR demonstrated the importance of hydrogen bonding of the oxygen in the O-glycosidic linkage to CD1d [48,60]. Without this linkage, the galactose headgroup was in a sub-optimal orientation when bound to CD1d, resulting in a lower TCR affinity compared to αGalCer/CD1d complexes.

Several C-glycoside analogs with a double bond were synthesized to try to generate a glycolipid providing a more fixed orientation of the galactose headgroup, in the expectation that this would activate iNKT cells to produce a strong Th1 response [61]. One of these, GCK127 had an E-olefin linker instead of a CH₂ glycosidic linkage. This molecule activated both mouse and human iNKT cells, albeit it was less potent than αGalCer [61]. The O-glycosidic linkage has also been modified by replacing the oxygen with a sulfur atom. The α-S-GC molecule induced a more Th2 skewed cytokine profile in mice and did not lead to increased survival in a tumor model [62]. A sulfur linkage was proposed to have a similar conformation to an oxygen bond, because although a sulfur atom is larger than oxygen, the bond angle is less than an O-glycosidic linkage and a thioglycosidic linkage would be less susceptible to enzymatic cleavage [63]. However, in vivo studies in mice indicated that α-S-GC did not lead to iNKT cell proliferation or cytokines. The authors proposed that the α-S-GC compound would lack some key hydrogen bonds when bound to CD1d, but this remains a conjecture. Another group synthesized the same compound and showed that although it did not stimulate mouse iNKT cells, it could activate human iNKT cells, causing cytokine secretion and iNKT cell-induced maturation signals in human DCs [64]. This is an intriguing counter example of species specificity of iNKT cell reactivity, compared to C-glycoside, which only works to activate mouse iNKT cells but not those from humans.

Lipid chain modifications
The sphingoid base is a defining property of the GSL antigens that activate iNKT cells. The most commonly found
sphingosine chain length in animal tissues is the aliphatic C: 18 chains; however, the number of carbon lengths can range from 14 to more than 27, and the sphingosine can have a wide variety of saturation levels and branched modifications [65]. The phytosphingosine of αGalCer [Fig. 2], with a hydroxyl group at C-4, differs from the more common natural sphingosine, which typically contains a trans double bond between C-4 and C-5. OCH is a compound with a phytosphingosine shortened by several carbon atoms [Fig. 2] [66]. This lipid antigen induced a more IL-4 dominated or Th2 profile. When injected into mice, OCH was shown to reduce the symptoms of experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis [66]. The further shortening of the sphingoid chain also led to a Th2 cytokine profile [67]. Different alterations of the sphingoid base can have an opposite polarizing effect on the cytokine response. For example, SMC124 is a synthetic Th1 skewing GSL similar to αGalCer but with a sphingoid base chain increased to 22 carbons with the addition of a cyclopropyl group at C11-12 [Figs. 2 and 3]. It was designed to mimic partially a naturally occurring GSL called plakoside A [68]. The results from structural studies of OCH and SMC124 bound to mouse CD1d suggest that the length of the lipid chain packed within the F’ pocket of CD1d may alter the presentation of the GSL [68]. The longer, bulkier chain of SMC124 may anchor the lipid more deeply within the antigen-presenting molecule, thereby prolonging antigen presentation, which may, for reasons that have not been completely elucidated, contribute to Th1 cytokine skewing. Conversely, OCH does not have a long chain to anchor CD1d and may have a reduced antigen presentation time.

The acyl chain of a number of synthetic GSL antigens is typically longer than the sphingoid base. For αGalCer, the acyl chain is an unbranched and fully saturated 26 carbons long. C20:2 is a GSL antigen containing a di-unsaturated and shorter, 20 carbon, and acyl chain [Fig. 2] [69]. This compound was identified in a screen of multiple αGalCer analogs with shorter acyl chains, all of which induced an enhanced Th2 cytokine profile [67]. The decrease in the carbon chains of the lipid, either in the acyl chain or in the sphingoid base, is proposed to destabilize the interactions between the lipid and CD1d. Indeed, when the lipid chains become too short, the interaction of the lipid and the CD1d is too unstable for any CD1d/[αGalCer] complexes to be detected in mammals and are therefore “foreign” epitopes. However, the analysis of iNKT cell differentiation in the thymus indicated that there had to be a self-ligand that could positively select these cells. A β-Linkage of sugar to the ceramide lipid does occur naturally in mammals, β-anomeric GSLs are part of cellular membranes [74,75]. β-linkages therefore were considered to be candidates for the major self-ligands [76]. Mice lacking βGalCer synthase, and thus lacking βGalCer, have normal iNKT cell development [77], and while mice treated with this compound have decreased iNKT cells in vivo, there was no detectable cytokine signal [78]. βGluCer, having glucose instead of galactose, is both an anabolic and catabolic GSL pathway metabolic intermediate [79], and it decreases in vitro iNKT cell proliferation [80] and is accumulated in patients with Gaucher’s disease, which have an increase in iNKT cells [81]. Surprisingly, while zManCer fails to activate iNKT cells, βManCer is an iNKT cell ligand capable of inducing a protective anti-tumor response [82]. This anti-tumor ligand operates through the induction of TNFα and nitric oxide, without IFN-γ, and it does not induce anergy, a side effect of some other strong iNKT cell ligands [83].

Because iNKT cells originate in the thymus, it was assumed that there must be some endogenous ligand(s) that participate in their positive selection. The hunt for endogenous ligands turned up several candidates including, iso-globotrihexosylceramide (iGb3), plasmalogens lysophosphatidylethanolamine [84], lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylinositol, phosphatidylcholine, phosphatidylserine, phosphatic acid βGluCer, βGalCer [85], and even a peptide from mouse collagen [75,81,86–89]. The structures of some of these are shown in [Fig. 4] iGb3, the first identified self-ligand [86], was crystallized, and it was shown that the mouse CD1d molecule can bind iGb3 [Fig. 5] [80]. When CD1d is loaded with iGb3, it forms a complex with the iNKT cell TCR in which the lipid proximal sugar is moved into a conformation similar to α-linked ligands. The terminal sugar of iGb3 forming novel contacts with CD1d [Fig. 5] [91,92]. However, the validity of such a compound as an endogenous ligand has been clouded by reports that suggest mice lacking iGb3 synthase, essential for iGb3 formation, still have a normal iNKT cell population [93]. In addition, it has been claimed that human CD1d cannot present iGb3 because of the glycine-tryptophan difference mentioned above [94], and iGb3 is not present in

Endogenous ligands

When the initial antigens for iNKT cells were discovered, it was predicted that the linkage of the sugar to the lipid could only be α-anomeric, and a β-linkage would not lead to iNKT cell activation [37,73]. This was presumed as logical as the α-anomeric form as well as D-glycosylceramides were not thought to be detected in mammals and are therefore “foreign” epitopes. However, the analysis of iNKT cell differentiation in the thymus indicated that there had to be a self-ligand that could positively select these cells. A β-Linkage of sugar to the ceramide lipid does occur naturally in mammals, β-anomeric GSLs are part of cellular membranes [74,75]. β-linkages therefore were considered to be candidates for the major self-ligands [76]. Mice lacking βGalCer synthase, and thus lacking βGalCer, have normal iNKT cell development [77], and while mice treated with this compound have decreased iNKT cells in vivo, there was no detectable cytokine signal [78]. βGluCer, having glucose instead of galactose, is both an anabolic and catabolic GSL pathway metabolic intermediate [79], and it decreases in vitro iNKT cell proliferation [80] and is accumulated in patients with Gaucher’s disease, which have an increase in iNKT cells [81]. Surprisingly, while zManCer fails to activate iNKT cells, βManCer is an iNKT cell ligand capable of inducing a protective anti-tumor response [82]. This anti-tumor ligand operates through the induction of TNFα and nitric oxide, without IFN-γ, and it does not induce anergy, a side effect of some other strong iNKT cell ligands [83].
mouse or human thymus [95]. Therefore, iGb3 cannot be a required self-ligand for iNKT cells. β-Glucosyl ceramide was identified as another endogenous ligand for iNKT cells. With a structure very similar to αGalCer, and data indicating that this lipid accumulated in the presence of a microbial infection [96], as well as tumor prevention data [97], it seemed very logical that this ligand could activate iNKT cells. However, recent data has indicated that the activation of iNKT cells in this study could be due to contaminating trace α-anomeric lipids, possibly generated during synthesis of β-glycolipids [98,99]. Regardless of the antigen, it is entirely possible that these self-ligands serve as not only a selection mechanism but also a means to get over an activation threshold when iNKT cells are activated by cytokines such as IL-12, IL-18, or IFN-1 [100–103].

**Bacterial antigens for invariant natural killer T-cells**

*Mycobacterium tuberculosis*

The first lipid antigens identified for any T-lymphocytes were lipids from Mycobacteria presented by Group 1 CD1 molecules [104–106]. These bacteria have an unusual outer waxy coating, comprised of different lipids, which is used to evade immune clearance. A screen of CD1d binding mammalian and Mycobacterium lipids identified phosphatidylinositol tetramannoside (PIM4) [107] isolated from a related bacterium, *Mycobacterium bovis* bacillus, a cause of bovine tuberculosis. The structure of a similar lipid, PIM3, bound to CD1d allowed for modeling of the PIM4 molecule in the CD1d groove [108]. However, a synthetic PIM4 molecule was shown to not stimulate iNKT cells [109], highlighting the need to compare the outcomes with synthetic and purified lipids. Subsequent work showed that Type II NKT cells with diverse TCRs could recognize different phospholipids from *Mycobacterium tuberculosis*. [110].

*Sphingomonas* spp.

*Sphingomonas* spp. was the first bacteria unambiguously shown to have antigens for iNKT cells. *Sphingomonas* are commensal bacteria of the human intestine, and there is evidence that commensal bacteria affect the number and function of iNKT cells [73,111–113]. Although not highly pathogenic, *Sphingomonas* includes more than 30 species that live in a wide variety of environments including soil and seawater. *Sphingomonas paucimobilis* is the most pathogenic, and it may be an opportunistic pathogen associated with suppression of the immune system [114]. As early as 2000, purification of GSLs from *Sphingomonas* bacteria was performed and it was noted that bacterial synthesis of different lipids can change depending on environmental factors [115–117]. There is an unusually high presence of GSLs in this α-Proteobacteria, instead of the LPS that is otherwise commonly found in Gram-negative bacteria [118]. In 2005, using both purified and synthetic material, several strains of *Sphingomonas* bacteria were shown to have antigens for iNKT cells including *S. paucimobilis*, *Sphingomonas capsulate*, and *Sphingomonas yanoikuyae* [73,119]. From these organisms, GSLs were isolated that had very strong structural similarities to αGalCer. For example, from *S. paucimobilis*, GSL-1 was isolated α-glucuronosylceramide compound, and from *S. yanoikuyae* α-

---

**Fig. 4** – Proposed endogenous ligands for invariant natural killer T-cells. Top: Crystal structures of tri-molecular complexes and the corresponding glycosphingolipid antigen structures are indicated. Bottom: Phospholipid-containing putative self-antigens.
galacturonosylceramide originally called GSL-1'. These two lipids are highly similar but differ only in their carbohydrate head groups; having a glucuronic acid versus galacturonic acid (GalA). Since their discovery, GSL-1 has been renamed as GalA-GSL to indicate the presence of GalA [Fig. 6]. This family of Sphingomonas-derived compounds also contains some with additional saccharide groups including tri- and tetra-saccharides known as GSL-3 and GSL-4, respectively. While the monosaccharide-containing GSL antigens activate iNKT cells in vivo and in vitro, [73,119,120] they are all weaker than αGalCer. For example, the INKT cell TCR affinity for GalA-GSL/CD1d is 50-fold weaker than for the αGalCer/CD1d complex [23]. The GSLs with oligosaccharide headgroups are not antigenic or do not activate as well as their monosaccharide counterparts, possibly due to a failure of the APCs to reduce the structures to a monosaccharide form in lysosomal compartments [46,121].

Borrelia burgdorferi
Whereas Sphingomonas spp. is not considered pathogenic, another source of iNKT cell antigens is from the pathogenic spirochete Borrelia burgdorferi. These bacteria, transmitted to humans by Ixodes scapularis (deer tick) bites, are the cause of Lyme disease, which is currently the most common vector-borne disease in the United States [122]. The immune response of mice to B. burgdorferi infection is partially CD1d dependent as a strain of mice resistant to Lyme arthritis had symptoms when the gene encodingCD1d was deleted [123]. Furthermore, mice lacking CD1d had decreased pathogen-specific antibodies [124]. B. burgdorferi-induced pathogenesis was increased in Jα18 deficient mice, which cannot form the invariant iNKT cell α-chain. In C57BL/6 mice, the absence of iNKT cells led to increased replication of spirochetes in the joint, delayed clearance, and arthritis [125,126] while Jα18 deficient mice on the BALB/c background had increased cardiitis [127]. Analysis of lipids from B. burgdorferi detected a series of abundant galactosyl diacylglycerols (DAGs) including BbGL-2 [109]. BbGL-2 was shown to activate iNKT cells in purified and synthetic forms. BbGL-2 was the first reported iNKT cell antigen that is not a GSL; it contains a α-galactose saccharide group with an α-anomeric glycosidic bond and is a DAG lipid, with lipid chains that vary in length and degree of saturation. The most highly potent of these in mice was BbGL-2c [Fig. 6], with C18:1 oleic acid in the sn-1 position and C16:0 palmitic acid in the sn-2 position [109] [Fig. 6]. Structural characterization of multiple different DAG antigens showed how alteration of the lipid chains determines the binding mode. The sn-1 linked fatty acid is capable of binding to either A' or F' pockets of mouse CD1d, with C18:1 oleic acid preferring the A' pocket [23]. The different binding modes determine how the exposed saccharide group is oriented for recognition by the TCR. Structural analysis demonstrated that the orientation of the BbGL-2c allowed for an optimal configuration compared to another DAG lipid with two unsaturated fatty acid chains [23]. Interestingly, in humans, the optimal sn-1 and sn-2 fatty acids are different because of the role that the position 153 tryptophan in the human CD1d α2 helix plays in orienting the exposed sugar.

Streptococcus pneumonia
Streptococcus pneumonia is a Gram-positive bacterium that not only leads to pneumonia, but also causes potentially lethal
bacteremia, otitis media, and meningitis. iNKT cells were shown to be protective in mice following pulmonary *S. pneumoniae* infection [128], and this protective response was linked to IFN-γ production by the iNKT cells [129]. The lipids of this bacterium were subjected to electrospray mass spectrometry analysis and two highly abundant DAGs were isolated: a monosaccharide linked DAG, α-glucosyl diacylglycerol (GlcDAG) [Fig. 6], and a disaccharide linked DAG, α-galactosyl GlcDAG (GalGlcDAG) [130]. Like the *B. burgdorferi* antigen, the DAG from *S. pneumoniae* has α-linked hexose sugar in the sn-3 position but is a glucose rather than galactose. This antigen has palmitic acid (C16:0) in the sn-1 position, and a vaccenic acid, a C18:1 fatty acid with a C11-C12 unsaturated bond, in the sn-2 position. The ternary crystal structure of GlcDAG bound to mouse CD1d with the iNKT cell TCR engaged shows that the vaccenic acid allows for a novel conformational change causing a re-orienting of the axial 4′-hydroxyl group of glucose to allow for the TCR to engage in a conserved binding motif [131].

*Helicobacter pylori*

*Helicobacter pylori* is a common, Gram-negative spiral bacterium that causes stomach problems in some individuals including gastritis, peptic ulcer, duodenal ulcer, lymphoma, and gastric cancer [132]. Certain *H. pylori* lipid extracts have been shown to expand iNKT cells and to play a beneficial role in clearing the bacterium [133,134]. This bacterium synthesizes cholesteryl α-glucosides using host-derived cholesterol. Although one study presented data indicating that cholesterol glucosylation allows *H. pylori* to evade phagocytosis by macrophages [135], these compounds also were shown to be recognized by iNKT cells, and the absence of iNKT cells in mice was correlated with increased *H. pylori* infection [134]. In a different study, mice were protected from asthma symptoms by administering an *H. pylori*, cholesterol-containing, synthetic glycolipid called PI57 [Fig. 7] [133], although this compound activated iNKT cells in both mice and humans, as determined by immune assays, biochemical analysis of TCR interaction with the cholesteryl α-glucoside complex with CD1d, and structural analysis showing how a cholesterol-containing antigen binds to CD1d, have not been reported.

**Fungal antigens for invariant natural killer T-cells**

Recently, it was reported that *Aspergillus fumigatus* contains a glycolipid antigen that can activate iNKT cells. *Aspergillus* is a ubiquitous fungus, and although exposure through inhalation is almost a daily occurrence, the spores or conidia can lead to infections, most commonly in the lungs and sinuses, and furthermore, Aspergillus exposure can contribute to asthma [136]. Previously, it had been shown that iNKT cells were activated by β-1,3-glycans from *Aspergillus*, which triggered IL-12 secretion from APCs that mediated the activation of iNKT cells, but which also required recognition CD1d-presented self-antigens [137]. In the more recent study implicating a microbial lipid in iNKT cell activation, the lipids of the two most common strains of *Aspergillus*, *A. fumigatus*, and *Aspergillus niger* were fractionated and tested against primary iNKT cell lines, and the GSL asperamide B [Fig. 7] was identified as an antigen for mouse and human iNKT cells. Asperamide B is a β-linked glucosylceramide, which is different from any of the previously described α-linked exogenous ligands. It possesses a 9-methyl-4,8-sphingadienine chain, commonly found in fungi [65] and a β-g unsaturated acyl chain with an α-hydroxyl group [138]. Both purified and synthetic asperamide B were able to activate iNKT cells, and mice exposed to asperamide B experienced airflow hyperreactivity, a feature of asthma, within 24 h [139].

**Protozoan antigens for invariant natural killer T-cells**

The glucosylphosphatidylinositol (GPI) anchors of surface proteins from *Plasmodium falciparum* and *Trypanosoma brucei* could expand iNKT cells, and this expansion was CD1d dependent [140]. A subsequent study, however, contradicted the earlier finding that reported that the production of *Plasmodium* anti-circumsporozoite IgG was MHC Class II independent, and by implication, iNKT cell dependent. These investigators also reported that GPI anchors could not induce iNKT cell activation [141]. More recently, a phosphoinositol antigen known as EhPI [Fig. 7] was isolated from a pool of lipopeptidophosphogycans from *Entamoeba histolytica* trophozoites and was shown to activate iNKT cells [142]. *E. histolytica* can be fatal, especially in the developing world, as it leads to amoebiasis, a diarrheal disease [143]. There are two isoforms of EhP, a and b, with the only difference between them being the acylation of inositol. Only the diacylated EhPIb [Fig. 7] stimulated iNKT cells. This lipid caused IFN-γ activation of iNKT cells that was dependent not only on CD1d but also on IL-12 production through Toll-like receptor signaling of APCs [142].

**Summary**

In conclusion, over the past two decades, knowledge about the specificity of iNKT cells has grown dramatically. Synthetic
agonists have been synthesized that bind with different degrees of stability to CD1d and that are able to preferentially skew the global immune response. Several natural antigens for iNKT cells have been identified, and they are both self-antigens that originate from antigen-presenting cells or foreign antigens from commensal or pathogenic microbes. It has been shown in several cases that the protective responses to pathogenic microbes depend on iNKT cell activation. The iNKT cell TCR can recognize these different structures, which are mostly glycolipids. A conserved docking motif of the iNKT cell TCR has been characterized through dozens of structural studies and is nearly always present, in some cases through a large accommodation of the antigen. Much work has been done to understand the mechanism of antigen recognition and the therapeutic potential of iNKT cells [36,144–146], and the hope is that this detailed biochemical knowledge can be harnessed to realize the therapeutic potential of these cells.

**REFERENCES**

[1] Yankelevich B, Knobloch C, Nowicki M, Dennert G. A novel cell type responsible for marrow graft rejection in mice. T cells with NK phenotype cause acute rejection of marrow grafts. J Immunol 1989;142:3423–30.

[2] Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998;188:1529–34.

[3] Exley MA, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Vv24+ CD4+CD8− T cells. J Exp Med 1997;186:109–20.

[4] Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002;110:793–800.

[5] Tangri S, Brossay L, Burdin N, Lee DJ, Kronenberg M. Presentation of peptide antigens by mouse CD1 requires endosomal localization and protein antigen processing. Proc Natl Acad Sci U. S. A. 1998;95:14314–9.

[6] Liu Y, Teige A, Mondoc E, Ibrahim S, Holmdahl R, Issazadeh-Navikas S. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice. J Clin Invest 2011;121:249–64.

[7] Bendelac A, Lantz Q, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995;268:863–5.

[8] Li Y, Girardi E, Wang J, Yu ED, Painter GF, Kronenberg M, et al. The Vv14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode. J Exp Med 2010;207:2383–93.

[9] Godfrey DJ, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what’s in a name? Nat Rev Immunol 2004;4:231–7.

[10] Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000;192:741–54.

[11] East JE, Kennedy AJ, Webb TJ. Raising the roof: the preferential pharmacological stimulation of Th1 and Th2 responses mediated by NKT cells. Med Res Rev 2014;34:445–76.

[12] Natori T, Morita M, Akimoto K, Koezuka Y. Agelasphins, novel antitumor and immunostimulatory cerebrosides from the marine sponge agelas-mauritianus. Tetrahedron 1994;50:2771–84.

[13] Akimoto K, Natori T, Morita M. Synthesis and stereochemistry of agelasphin-9b. Tetrahedron Lett 1993;34:5593–6.

[14] Morita M, Motoki K, Akimoto K, Natori T, Sakai T, Sawada E, et al. Structure-activity relationship of α-galactosylceramides against B16-bearing mice. J Med Chem 1995;38:2176–87.

[15] Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, et al. Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 2008;57:337–45.

[16] Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, et al. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005;11:1910–7.

[17] Godola SD, Koch M, Marles-Wright J, Lissin NM, Shepherd D, Matulis G, et al. Structure and binding kinetics of three different human CD1d-α-galactosylceramide-specific T cell receptors. J Exp Med 2006;203:699–710.

[18] Nieda M, Okai M, Tazibkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic activation of Vv24+Vb11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004;103:383–9.

[19] Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005;201:1503–17.

[20] Cohen NR, Garg S, Brenner MB. Antigen presentation by CD1 ligands, T cells, and NKT cells in microbial immunity. Adv Immunol 2009;102:1–94.

[21] Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol 2007;7:529–41.

[22] Zajonc DM, Kronenberg M. CD1 mediated T cell recognition of glycolipids. Curr Opin Struct Biol 2007;17:521–9.

[23] Wang J, Li Y, Kinjo Y, Mac TT, Gibson D, Painter GF, et al. Lipid binding orientation within CD1d affects recognition of Borrelia burgdorferi antigens by NKT cells. Proc Natl Acad Sci U. S. A. 2010;107:1535–40.

[24] Cernadas M, Sugita M, van der Wel N, Cao X, Gumperz JE, Maltsev S, et al. Lyosomal localization of murine CD1d mediated by AP-3 is necessary for NK T cell development. J Immunol 2003;171:4149–55.

[25] Zhou D, Cantu 3rd C, Sagiv Y, Schrantly N, Kulkarni AB, Qi X, et al. Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 2004;303:523–7.

[26] Im JS, Arora P, Bricard G, Molano A, Venkataswamy MM, Baine I, et al. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 2009;30:888–98.

[27] Dougan SK, Kaser A, Blumberg RS. T cell activation by CD1 and lipid antigens. Berlin, Heidelberg: Springer Berlin Heidelberg; 2007.

[28] Canchis PW, Bhan AK, Landau SB, Yang L, Balk SP, Blumberg RS. Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d. Immunology 1993;80:561–5.

[29] Blumberg RS, Terhorst C, Bleicher P, McDermott FV, Allan CH, Landau SB, et al. Expression of a non-polymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells. J Immunol 1991;147:2518–24.

[30] Barral P, Polzella P, Bruckbauer A, van Rooijen N, Besra GS, Cerundolo V, et al. CD169+ macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 2010;11:303–12.
Kamada N, Iijima H, Kimura K, Harada M, Shimizu E, Koch M, Stronge VS, Shepherd D, Gadola SD, Mathew B, Arora P, Baena A, Yu KO, Saini NK, Kharkwal SS, Trappeniers M, Goormans S, Van Beneden K, Decruy T, Long X, Deng S, Mattner J, Zang Z, Zhou D, McNary N, et al. Molecular basis of lipid antigen presentation by CD1d-restricted NKT cells. Int Immunol 2001;13:853–61.

Brossay L, Naidenko O, Burdin N, Matsuda J, Sakai T, Kronenberg M. Structural requirements for galactosylceramide recognition by CD1d-restricted NKT cells. J Immunol 1998;161:5124–8.

Trappeniers M, Goormans S, Van Beneden K, Decruy T, Sil Motohashi, et al. Crucial amino acid residues of mouse CD1d for glycolipid ligand presentation to Vα14 NKT cells. EMBO J 2011;30:2294–305.

Aspeslagh S, Nemcovc M, Pauwels N, Venken K, Wang J, Van Caenbergh S, et al. Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection. J Immunol 2013;191:2916–25.

Zhou XT, Forestier C, Goff RD, Li C, Teyton L, Bendelac A, et al. Synthesis and NKT cell stimulating properties of fluorophore- and biotin-appended 6'-amino-6'-deoxy-galactosylceramides. Org Lett 2002;4:1267–70.

Yu SH, Park JJ, Chung SK. Practical syntheses of optically active carbagalactose and their potential application to the carbocyclic analogues of KRN7000. Tetrahedron Asymmetry 2006;17:3030–6.

Tashiro T, Nakagawa R, Hikoraka T, Inoue S, Watarai H, Taniguchi M, et al. RCAI-37, 56, 59, 60, 92, 101, and 102, cyclitol and carbasugar analogs of KRN7000: their synthesis and bioactivity for mouse lymphocytes to produce Th1-biased cytokines. Bioorg Med Chem 2009;17:6360–73.

Tashiro T, Sekine-Kondo E, Shigeura T, Nakagawa R, Inoue S, Omori-Miyake M, et al. Induction of Th1-biased cytokine production by α-carba-GalCer, a neoglycolipid ligand for NKT cells. Int Immunol 2010;22:319–28.

Yoshiga Y, Goto D, Segawa S, Horikoshi M, Hayashi T, Matsumoto I, et al. Activation of natural killer T cells by α-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis. Clin Exp Immunol 2011;164:236–47.

Harrak Y, Barra CM, Bedia C, Delgado A, Castano AR, Llebaria A. Aminocyclitol-substituted phytoceramides and their effects on iNKT cell stimulation. ChemMedChem 2009;4:1608–13.

Kerzerho J, Yu ED, Barra CM, Aliari-Pahissa E, Girardi E, Harrak Y, et al. Structural and functional characterization of a novel nonglycosidic type I NKT agonist with immunomodulatory properties. J Immunol 2012;188:2254–65.

Schmie J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J Exp Med 2003;198:1631–41.

Franck RW, Tsuji M. α-C-galactosylceramides: synthesis and immunology. Acc Chem Res 2006;39:692–701.

Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Chen G, et al. Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U. S. A 2006;103:11252–7.

Patel O, Cameron G, Pellicci DG, Liu Z, Byun HS, Beddoo T, et al. NKT TCR recognition of CD1d-α-C-galactosylceramide. J Immunol 2011;187:4705–13.

Li X, Chen G, Garcia-Navarro R, Franck RW, Tsuji M. Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells. Immunology 2009;127:216–25.

Chang YJ, Huang JR, Tsai YC, Hung JT, Wu D, Fuji M, et al. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci U. S. A 2007;104:10299–304.

Blauvelt ML, Khallili M, Jaung W, Paulsen J, Anderson AC, Brian Wilson S, et al. α-S-GalCer: synthesis and evaluation for iNKT cell stimulation. Bioorg Med Chem Lett 2008;18:6374–6.

Hogan AE, O’Reilly V, Dunne MR, Dore KT, Zeng SG, O’Brien C, et al. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-C-galactosylceramide. Clin Immunol 2011;140:196–207.

Merrill AH. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 2011;111:6387–422.
Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001;413:531–4.

Goff RD, Gao Y, Mattner J, Zhou D, Yin N, Cantu 3rd C, et al. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 2004;126:13602–3.

Tyznik AJ, Farber E, Girardi E, Birkholza A, Li Y, Chitale S, et al. Glycolipids that elicit IFN-γ-biased responses from natural killer T cells. Chem Biol 2011;18:1620–30.

Yu KO, Im JS, Molano A, Dutronc Y, Illarionov PA, Forestier C, et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc Natl Acad Sci U. S. A 2005;102:3833–8.

Fujii M, Wu D, Garcia-Navarro R, Ho DD, Tsuji M, Wong CH. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J Am Chem Soc 2006;128:9022–3.

Padte NN, Boente-Carrera M, Andrews CD, McManus J, Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 2005;35:1692–706.

Goni FM, Alonso A. Biophysics of sphingolipids I. Membrane properties of sphingosine, ceramides and other simple sphingolipids. Biochim Biophys Acta 2006;1758:1902–7.

Sonino S, Mauri L, Chigorno V, Prinetti A. Gangliosides as components of lipid membrane domains. Glycobiology 2007;17:18–13R.

Parekh SV, Singh AK, Wilson MT, Olivares-Villagómez D, Bebzradica JS, Inazawa H, et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J Immunol 2004;173:7809–14.

Stanic AK, de Silva AD, Park JJ, Sirram V, Ichikawa S, Hirabayashi Y, et al. Defective presentation of the CD1d-restricted natural α(2-3)Fucα(1-6)Galβ(1-4)GlcNAcβ(1-3)Galβ(1-4)Glc ceramide by dendritic cells and macrophages. J Immunol 2003;167:709–16.

Ortaldo JR, Young HA, Winkler-Pickett RT, Bere Jr EW, Murphy WJ, Willout RH. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol 2004;172:943–53.

Lalazar G, Preston S, Zigmond E, Ben Yáacon C, Iain Y. Glycolipids as immune modulatory tools. Mini Rev Med Chem 2006;6:1249–53.

Margalit M, Abu Gazala S, Alper R, Elnav E, Klein A, Doviner V, et al. Glucocerebrosides: promiscuous ameliorates ConA hepatitis by inhibition of NKT lymphocytes. J Physiol Gastrointest Liver Physiol 2005;289:G917–25.

Balreira A, Lacerda I, Miranda CS, Arosa FA. Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model. Br J Haematol 2005;129:767–76.

O’Konek JJ, Illarionov P, Khursigara DS, Ambrosino F, Izhak L, Castillo 2nd BF, et al. Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity. J Clin Invest 2011;121:683–94.

O’Konek JJ, Kato S, Takao S, Ishak L, Xia Z, Illarionov P, et al. β-mannosylceramide activates type I natural killer T cells to induce tumor immunity without inducing long-term functional energy. Clin Cancer Res 2013;19:4404–11.

Ni G, Li Z, Liang K, Wu T, De Libero G, Xia C. Synthesis and evaluation of immunostimulant psammanoglycosphosphatidylethanolamine and analogues for natural killer T cells. Bioorg Med Chem 2014;22:2966–73.

Mallevaey T, Clarke AJ, Scott-Browne JP, Young MH, Roisman LC, Pellicci DG, et al. A molecular basis for NKT cell recognition of CD1d-self-antigen. Immunity 2011;34:315–26.

Zhou D, Mattner J, Cantu 3rd C, Schrantz N, Yin N, Gao Y, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2006;306:1786–9.

Fox LM, Cox DG, Lockridge JL, Wang X, Chen X, Scharf L, et al. Recognition of lyso-phospholipids by human natural killer T lymphocytes. PLoS Biol 2009;7:e1000228.

Rauch J, Gumperz J, Robinson C, Skold M, Roy C, Young DC, et al. Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. J Biol Chem 2003;278:47508–15.

Gumperz JE, Roy C, Makowska A, Lum D, Supita M, Podrebarac T, et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000;12:211–21.

Zajonc DM, Savage PB, Bendelac A, Wilson IA, Teyton L. Crystal structures of mouse CD1d-iGb3 complex and its cognate Vα14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. J Mol Biol 2008;377:1104–16.

Yu ED, Girardi E, Wang J, Zajonc DM. Cutting edge: structural basis for the recognition of β-linked glycolipid antigens by invariant NKT cells. J Immunol 2011;187:2079–83.

Porubsky S, Speak AO, Luckow B, Berundolo V, Platt FM, Grone HJ. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci U. S. A 2007;104:5977–82.

Sanderson JP, Brennan PJ, Mansour S, Matulis G, Patel O, Lissin N, et al. CD1d protein structure determines species-selective antigenicity of isoglobotrihexosylceramide (iGb3) to invariant NKT cells. Eur J Immunol 2013;43:815–25.

Speak AO, Salmo M, Neville DC, Fontaine J, Priestman DA, Platt N, et al. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci U. S. A 2007;104:5971–6.

Brennan PJ, Tatituri RV, Brigm M, Kim EY, Tuli A, Sanderson JP, et al. Invariant natural killer T cell responses to invariant CD1d ligands in vivo depend upon the presence of isoglobotrihexosylceramide. J Immunol 2005;174:9511–21.

Inafuku M, Li C, Kanda Y, Kawamura T, Takeda K, Oku H, et al. Beta-glucosylceramide administration (i.p.) activates natural killer T cells and prevents tumor metastasis in mice. J Immunol 2011;187:2079–83.

Kain L, Webb B, Anderson BL, Deng S, Holt M, Costanzo A, et al. The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian α-linked glycosphingolipids. Immunity 2014;41:543–54.
Tyznik AJ, Tupin E, Nagarajan NA, Her MJ, Benedict CA, Kronenberg M. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J Immunol 2008;181:4452–6.

Paget C, Maillévaey T, Speak AO, Torres D, Fontaine J, Sheehan KC, et al. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity 2007;27:597–609.

Nagarajan NA, Kronenberg M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol 2007;178:2706–13.

Wesley JD, Tessmer MS, Chaukos D, Brossay L. NK cell-like behavior of Vα14Iκ NKT cells during MCMV infection. PLoS Pathog 2008;4:e1000106.

Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted αβ+ T cells. Nature 1994;372:691–4.

Moody DB, Ulrichs T, Mülecker W, Young DC, Gurcha SS, Grant E, et al. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 2000;404:884–8.

Porcelli S, Morita CT, Brenner MB. CD1b restricts the response of human CD4+ T lymphocytes to a microbial antigen. Nature 1992;360:593–7.

Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, Wingender G, Stepniak D, Krebs P, Lin L, McBride S, Wei B, Kawasaki K, Moll H, Knirel YA, Seydel U, Zerrahn J, Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, et al. Role of interferon-γ and charged glycosphingolipids. Immunity 2007;214:289–300.

Lee WY, Moriarty TJ, Wong CH, Zhou H, Strierer RM, van Rooijen N, et al. An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol 2010;11:295–302.

Tupin E, Benhnia MR, Kinjo Y, Patsey R, Lena CJ, Haller MC, et al. NKT cells prevent chronic joint inflammation after infection with Borrelia burgdorferi. Proc Natl Acad Sci U. S. A 2005;102:19863–8.

Olson Jr CM, Bates TC, Izadi H, Radolf JD, Huber SA, Boyson JE, et al. Local production of IFN-γ by invariant NKT cells modulates acute Lyme carditis. J Immunol 2009;182:3728–34.

Kawakami K, Yamamoto N, Kinjo Y, Miyagi K, Nakasone C, Uezu K, et al. Critical role of Vα14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur J Immunol 2003;33:3322–30.

Nakamatsu M, Yamamoto N, Hatta M, Nakasone C, Kinjo T, Miyagi K, et al. Role of interferon-γ in Vα14+ natural killer T cell-mediated host defense against Streptococcus pneumoniae infection in murine lungs. Microbes Infect 2007;9:364–74.

Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, et al. Invariant natural killer T cells recognize glycolipids from pathogenic gram-positive bacteria. Nat Immunol 2011;12:966–74.

Girardi E, Yu ED, Li Y, Tarumoto N, Pei B, Wang J, et al. Unique interplay between sugar and lipid in determining the antigenic potency of bacterial antigens for NKT cells. PLoS Biol 2011;9:e1001189.

Momtaz H, Dabiri H, Souod N, Gholami M. Study of bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001;7:167–202.

Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, Ho DD, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005;434:520–5.

Mattner J, DeBord KL, Issamil N, Goff RD, Cantu 3rd C, Zhou D, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005;434:525–9.

Kinjo Y, Pei B, Bufali S, Raju R, Richardson SK, Imamura M, et al. Natural Sphingomonas glycolipids vary greatly in their ability to activate natural killer T cells. Chem Biol 2008;15:654–64.

Tilly K, Rosa PA, Stewart PE. Biology of infection with Borrelia burgdorferi. Infect Dis Clin North Am 2008;22:217–34.

Kumar H, Belperron A, Barthold SW, Bockenstedt LK. Cutting edge: CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi. J Immunol 2000;165:4797–801.

Belperron AA, Dailey CM, Bockenstedt LK. Infection-induced marginal zone B cell production of Borrelia henselae-specific antibody is impaired in the absence of CD1d. J Immunol 2005;174:5698–609.

Lee WY, Moriarty TJ, Wong CH, Zhou H, Strierer RM, van Rooijen N, et al. Intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol 2010;11:295–302.

Tupin E, Benhnia MR, Kinjo Y, Patsey R, Lena CJ, Haller MC, et al. NKT cells prevent chronic joint inflammation after infection with Borrelia burgdorferi. Proc Natl Acad Sci U. S. A 2005;102:19863–8.

Olson Jr CM, Bates TC, Izadi H, Radolf JD, Huber SA, Boyson JE, et al. Local production of IFN-γ by invariant NKT cells modulates acute Lyme carditis. J Immunol 2009;182:3728–34.

Kawakami K, Yamamoto N, Kinjo Y, Miyagi K, Nakasone C, Uezu K, et al. Critical role of Vα14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur J Immunol 2003;33:3322–30.

Nakamatsu M, Yamamoto N, Hatta M, Nakasone C, Kinjo T, Miyagi K, et al. Role of interferon-γ in Vα14+ natural killer T cell-mediated host defense against Streptococcus pneumoniae infection in murine lungs. Microbes Infect 2007;9:364–74.

Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, et al. Invariant natural killer T cells recognize glycolipids from pathogenic gram-positive bacteria. Nat Immunol 2011;12:966–74.

Girardi E, Yu ED, Li Y, Tarumoto N, Pei B, Wang J, et al. Unique interplay between sugar and lipid in determining the antigenic potency of bacterial antigens for NKT cells. PLoS Biol 2011;9:e1001189.

Momtaz H, Dabiri H, Souod N, Gholami M. Study of Helicobacter pylori genotype status in cows, sheep, goats and human beings. BMC Gastroenterol 2014;14:61.

Chang YJ, Kim HY, Albacker LA, Lee HH, Baumgarth N, Akira S, et al. Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. J Clin Invest 2011;121:57–69.

Ito Y, Vela JL, Matsumura F, Hoshino H, Tyznik A, Lee H, et al. Helicobacter pylori cholesterol α-glucosides contribute to its pathogenicity and immune response by natural killer T cells. PLoS One 2013;8:e78191.

Wunder C, Churin Y, Winau F, Warnecke D, Vieth M, Lindner B, et al. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori. Nat Med 2006;12:1030–8.

Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Aspergillus hypersensitivity and allergic bronchopulmonary
aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis 2009;13:936–44.

[137] Cohen NR, Tatituri RV, Rivera A, Watts GF, Kim EY, Chiba A, et al. Innate recognition of cell wall β-glucans drives invariant natural killer T cell responses against fungi. Cell Host Microbe 2011;10:437–50.

[138] Chaudhary V, Albacker LA, Deng S, Chuang YT, Li Y, Umetzu DT, et al. Synthesis of fungal glycolipid asperamide B and investigation of its ability to stimulate natural killer T cells. Org Lett 2013;15:5242–5.

[139] Albacker LA, Chaudhary V, Chang YJ, Kim HY, Chuang YT, Pichavant M, et al. Invariant natural killer T cells recognize a fungal glycosphingolipid that can induce airway hyperreactivity. Nat Med 2013;19:1297–304.

[140] Schofield L, McConville MJ, Hansen D, Campbell AS, Fraser-Reid B, Grusby MJ, et al. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science 1999;283:225–9.

[141] Molano A, Park SH, Chiu YH, Nosseir S, Bendelac A, Tsuji M. Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPs in NK T cell activation and antimalarial responses. J Immunol 2000;164:5005–9.

[142] Lotter H, González-Roldán N, Lindner B, Winau F, Isibasi A, Moreno-Lafont M, et al. Natural killer T cells activated by a lipopeptidophosphoglycan from Entamoeba histolytica are critically important to control amebic liver abscess. PLoS Pathog 2009;5:e1000434.

[143] Ralston KS, Solga MD, Mackey-Lawrence NM, Somlata, Bhattacharya A, Petri Jr WA. Trogocytosis by Entamoeba histolytica contributes to cell killing and tissue invasion. Nature 2014;508:526–30.

[144] Laurent X, Bertin B, Renault N, Farce A, Speca S, Milhomme O, et al. Switching invariant natural killer T (NKT) cell response from anticancerous to anti-inflammatory effect: molecular bases. J Med Chem 2014;57:5489–508.

[145] Anderson BL, Teyton L, Bendelac A, Savage PB. Stimulation of natural killer T cells by glycolipids. Molecules 2013;18:15662–88.

[146] Banchet-Cadeddu A, Hénon E, Dauchez M, Renault JH, Monneaux F, Haudrechy A. The stimulating adventure of KRN 7000. Org Biomol Chem 2011;9:3080–104.